Isolation and identification of renal cell carcinoma-derived peptides associated with GP96

Technology in Cancer Research and Treatment

Volumn 12, Issue 4, 2013, Pages 285-293

  Li, H Z ^a,b   Li, C W ^b   Li, C Y ^b   Zhang, B F ^a   Li, L T ^a   Li, J M ^b   Zheng, J N ^a   Chang, J W ^b  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Amino acid sequence; GP96 peptide complex; Mass spectrometry; Renal cell carcinoma; Vaccine

Indexed keywords

GLYCOPROTEIN GP 96; MONOCLONAL ANTIBODY; PEPTIDE; CANCER VACCINE; GLUCOSE REGULATED PROTEIN 94; MEMBRANE PROTEIN; PEPTIDE FRAGMENT; TUMOR PROTEIN;

AMINO ACID SEQUENCE; ARTICLE; CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOGENICITY; IN VITRO STUDY; KIDNEY CARCINOMA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN ISOLATION; PROTEIN PURIFICATION; SEQUENCE ANALYSIS; SOFT TISSUE TUMOR; WESTERN BLOTTING; CHEMISTRY; IMMUNOLOGY; ISOLATION AND PURIFICATION; KIDNEY TUMOR; MASS SPECTROMETRY; MOLECULAR WEIGHT;

AMINO ACID SEQUENCE; CANCER VACCINES; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; MEMBRANE GLYCOPROTEINS; MOLECULAR WEIGHT; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84880051585     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.7785/tcrt.2012.500326     Document Type: Article

References (34)

1. Rini, B. I., Rathmell, W. K., Godley, P. Renal cell carcinoma. Current Opinion in Oncology 20, 300-306 (2008) DOI: 10.1097/CCO.0b013e3282f9782b
2. Verra, N., de Jong, D., Bex, A., Batchelor, D., Dellemijn, T., Sein, J., Nooijen, W., Meinhardt, W., Horenblas, S., de Gast, G., Vyth-Dreese, F. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy. European Urology 48, 527-533 (2005). DOI: 10.1016/j.eururo.2005.03.031
3. Asemissen, A. M., Brossart, P. Vaccination strategies in patients with renal cell carcinoma. Cancer Immunology, Immunotherapy 58, 1169-1174 (2009). DOI: 10.1007/s00262-009-0706-7
4. Rivoltini, L., Castelli, C., Carrabba, M., Mazzaferro, V., Pilla, L., Huber, V., Coppa, J., Gallino, G., Scheibenbogen, C., Squarcina, P., Cova, A., Camerini, R., Lewis, J. J., Srivastava, P. K., Parmiani, G. Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma-and colon carcinoma-specific T cells. Journal of Immunology 171, 3467-3474 (2003). DOI
5. Tamura, Y., Peng, P., Liu, K., Daou, M., Srivastava, P. K. Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science 278, 117-120 (1997). DOI
6. Srivastava, P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innateand adaptive immune responses. Annual Review of Immunology 20, 395-425 (2002). DOI: 10.1146/annurev.immunol.20.100301.064801
7. Wood, C. G., Mulders, P. Vitespen: a preclinical and clinical review. Future Oncology 5, 763-774 (2009). DOI: 10.2217/fon.09.46
8. Gordon, N. F., Clark, B. L. The challenges of bringing autologous HSP-based vaccines to commercial reality. Methods 32, 63-69 (2004). DOI
9. Binder, R. J., Blachere, N. E., Srivastava, P. K. Heat shock protein-chaperoned peptides but not free peptides introduced into the cytosol are presented efficiently by major histocompatibility complex I molecules. The Journal of Biological Chemistry 276, 17163-17171 (2001). DOI: 10.1074/jbc.M011547200
10. Offringa, R. Antigen choice in adoptive T-cell therapy of cancer. Current Opinion in Immunology 21, 190-199 (2009). DOI: 10.1016/j.coi.2009.02.006
11. Srivastava, P. K. Purification of heat shock protein-peptide complexes for use in vaccination against cancers and intracellular pathogens. Methods 12, 165-171 (1997). DOI: 10.1006/meth.1997.0464
12. Liu, C., Ewing, N., DeFilippo, M. Analytical challenges and strategies for the characterization of gp96-associated peptides. Methods 32, 32-37 (2004). DOI
13. Callahan, M. K., Garg, M., Srivastava, P. K. Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation. Proceedings of the National Academy of Sciences of the United States of America 105, 1662-1667 (2008). DOI: 10.1073/pnas.0711365105
14. Binder, R. J., Srivastava, P. K. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD81 T cells. Nature Immunology 6, 593-599 (2005). DOI: 10.1038/ni1201
15. Suto, R., Srivastava, P. K. A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides. Science 269, 1585-1588 (1995). DOI
16. Randazzo, M., Terness, P., Opelz, G., Kleist, C. Active-specific immunotherapy of human cancers with the heat shock protein Gp96-revisited. International Journal of Cancer 130, 2219-2231 (2012). DOI: 10.1002/ijc.27332
17. Binder, R. J., Kelly, J. B. 3rd, Vatner, R. E., Srivastava, P. K. Specific immunogenicity of heat shock protein gp96 derives from chaperoned antigenic peptides and not from contaminating proteins. Journal of Immunology 179, 7254-7261 (2007). DOI
18. Breloer, M., Marti, T., Fleischer, B., von Bonin, A. Isolation of processed, H-2Kb-binding ovalbumin-derived peptides associated with the stress proteins HSP70 and gp96. European Journal of Immunology 28, 1016-1021 (1998). DOI
19. Meng, S. D., Gao, T., Gao, G. F., Tien, P. HBV-specific peptide associated with heat-shock protein gp96. Lancet 357, 528-529 (2001). DOI: 10.1016/S0140-6736(00)04050-2
20. Mazzaferro, V., Coppa, J., Carrabba, M. G., Rivoltini, L., Schiavo, M., Regalia, E., Mariani, L., Camerini, T., Marchiano, A., Andreola, S., Camerini, R., Corsi, M., Lewis, J. J., Srivastava, P. K., Parmiani, G. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 9, 3235-3245 (2003). DOI
21. Pilla, L., Patuzzo, R., Rivoltini, L., Maio, M., Pennacchioli, E., Lamaj, E., Maurichi, A., Massarut, S., Marchiano, A., Santantonio, C., Tosi, D., Arienti, F., Cova, A., Sovena, G., Piris, A., Nonaka, D., Bersani, I., Di Florio, A., Luigi, M., Srivastava, P. K., Hoos, A., Santinami, M., Parmiani, G. A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-alpha in metastatic melanoma patients. Cancer Immunology, Immunotherapy 55, 958-968 (2006). DOI: 10.1007/s00262-005-0084-8
22. Maki, R. G., Livingston, P. O., Lewis, J. J., Janetzki, S., Klimstra, D., Desantis, D., Srivastava, P. K., Brennan, M. F. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Digestive Diseases and Sciences 52, 1964-1972 (2007). DOI: 10.1007/s10620-006-9205-2
23. Eton, O., Ross, M. I., East, M. J., Mansfield, P. F., Papadopoulos, N., Ellerhorst, J. A., Bedikian, A. Y., Lee, J. E. Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma. Journal of Translational Medicine 8, 9 (2010). DOI: 10.1186/1479-5876-8-9
24. Belli, F., Testori, A., Rivoltini, L., Maio, M., Andreola, G., Sertoli, M. R., Gallino, G., Piris, A., Cattelan, A., Lazzari, I., Carrabba, M., Scita, G., Santantonio, C., Pilla, L., Tragni, G., Lombardo, C., Arienti, F., Marchianò, A., Queirolo, P., Bertolini, F., Cova, A., Lamaj, E., Ascani, L., Camerini, R., Corsi, M., Cascinelli, N., Lewis, J. J., Srivastava, P., Parmiani, G. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 20, 4169-4180 (2002). DOI
25. Testori, A., Richards, J., Whitman, E., Mann, G. B., Lutzky, J., Camacho, L., Parmiani, G., Tosti, G., Kirkwood, J. M., Hoos, A., Yuh, L., Gupta, R., Srivastava, P. K., Group, C. S. Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 26, 955-962 (2008). DOI: 10.1200/JCO.2007.11.9941
26. Wood, C., Srivastava, P., Bukowski, R., Lacombe, L., Gorelov, A. I., Gorelov, S., Mulders, P., Zielinski, H., Hoos, A., Teofilovici, F., Isakov, L., Flanigan, R., et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372, 145-154 (2008). DOI: 10.1016/S0140-6736(08)60697-2
27. Jonasch, E., Wood, C., Tamboli, P., Pagliaro, L. C., Tu, S. M., Kim, J., Srivastava, P., Perez, C., Isakov, L., Tannir, N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. British Journal of Cancer 98, 1336-1341 (2008). DOI: 10.1038/sj.bjc.6604266
28. Crane, C. A., Han, S. J., Ahn, B. J., Oehlke, J., Kivett, V., Fedoroff, A., Butowski, N., Chang, S. M., Clarke, J., Berger, M. S., McDermott, M. W., Prados, M. D., Parsa, A. T. Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research (2012). DOI: 10.1158/1078-0432.CCR-11-3358
29. Carlson, B. Research, conferences, and FDA actions. Biotechnology Healthcare 5, 7-16 (2008). DOI
30. Ménoret, A., Bell, G. Purification of multiple heat shock proteins from a single tumor sample. Journal of Immunological Methods 237, 119-130 (2000). DOI
31. Singh-Jasuja, H., Toes, R. E., Spee, P., Munz, C., Hilf, N., Schoenberger, S. P., Ricciardi-Castagnoli, P., Neefjes, J., Rammensee, H. G., Arnold-Schild, D., Schild, H. Cross-presentation of glycoprotein 96-associated antigens on major histocompatibility complex class I molecules requires receptor-mediated endocytosis. The Journal of Experimental Medicine 191, 1965-1974 (2000). DOI
32. Kurotaki, T., Tamura, Y., Ueda, G., Oura, J., Kutomi, G., Hirohashi, Y., Sahara, H., Torigoe, T., Hiratsuka, H., Sunakawa, H., Hirata, K., Sato, N. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. Journal of Immunology 179, 1803-1813 (2007). DOI
33. Nieland, T. J., Tan, M. C., Monne-van Muijen, M., Koning, F., Kruisbeek, A. M., van Bleek, G. M. Isolation of an immunodominant viral peptide that is endogenously bound to the stress protein GP96/GRP94. Proceedings of the National Academy of Sciences of the United States of America 93, 6135-6139 (1996). DOI
34. Linderoth, N. A., Simon, M. N., Hainfeld, J. F., Sastry, S. Binding of antigenic peptide to the endoplasmic reticulum-resident protein gp96/GRP94 heat shock chaperone occurs in higher order complexes. Essential role of some aromatic amino acid residues in the peptide-binding site. The Journal of Biological Chemistry 276, 11049-11054 (2001). DOI: 10.1074/jbc.M010059200